Study title:
FINESCHI-S, OKOLICSANYI-L.
L. OKOLICSANYI, CATTEDRA DI GASTROENTEROLOGIA, ISTITUTO DI SEMEIOTICA MEDIC
A, VIA A. GRAMSCI 14, 43100 PARMA, ITALY.
PATHOPHYSIOLOGY AND TREATMENT OF IRRITABLE BOWEL SYNDROME.
ARGOMENTI DI GASTROENTEROLOGIA CLINICA {ARGOMENTI-GASTROENTEROL- CLIN}, 1999
VOL/ISS/PG. 12/2 (49-59),FINESCHI-S, OKOLICSANYI-L.
L. OKOLICSANYI, CATTEDRA DI GASTROENTEROLOGIA, ISTITUTO DI SEMEIOTICA MEDIC
A, VIA A. GRAMSCI 14, 43100 PARMA, ITALY.
PATHOPHYSIOLOGY AND TREATMENT OF IRRITABLE BOWEL SYNDROME.
ARGOMENTI DI GASTROENTEROLOGIA CLINICA {ARGOMENTI-GASTROENTEROL- CLIN}, 1999
VOL/ISS/PG. 12/2 (49-59),
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Digestive System Diseases
|
Brands: Please see report, Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: TRIMEBUTINE |
ATC code: A03AA05 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|